Bipolar Disorder Manic Depression Market

DelveInsight's "Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Bipolar Depression market report provides current treatment practices, emerging drugs, Bipolar Depression market share of the individual therapies, current and forecasted Bipolar Depression market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Bipolar Depression treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030

Bipolar Depression Disease Understanding and Treatment Algorithm

The DelveInsight Bipolar Depression market report gives a thorough understanding of the Bipolar Depression by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 


Bipolar Depression Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Bipolar Depression. 


Bipolar Depression Treatment 

It covers the details of conventional and current medical therapies available in the Bipolar Depression market for the treatment of the condition. It also provides Bipolar Depression treatment algorithms and guidelines in the United States, Europe, and Japan. 

Bipolar Depression Epidemiology  

The Bipolar Depression epidemiology division provide insights about historical and current Bipolar Depression patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Bipolar Depression Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Bipolar Depression epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. 


Country Wise- Bipolar Depression Epidemiology 

The epidemiology segment also provides the Bipolar Depression epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

Bipolar Depression Drug Chapters

Drug chapter segment of the Bipolar Depression report encloses the detailed analysis of Bipolar Depression marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Bipolar Depression clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Bipolar Depression Marketed Drugs 

The report provides the details of the marketed product available for Bipolar Depression treatment. 


Bipolar Depression Emerging Drugs 

The report provides the details of the emerging therapies under the late and mid-stage of development for Bipolar Depression treatment. 

Bipolar Depression Market Outlook

The Bipolar Depression market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Bipolar Depression market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 


This segment gives a thorough detail of Bipolar Depression market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 


According to DelveInsight, Bipolar Depression market in 7MM is expected to change in the study period 2017-2030.


Bipolar Depression Key Findings

This section includes a glimpse of the Bipolar Depression market in 7MM.


The United States Bipolar Depression Market Outlook

This section provides the total Bipolar Depression market size and market size by therapies in the United States.


EU-5 Countries: Bipolar Depression Market Outlook

The total Bipolar Depression market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.


Japan Bipolar Depression Market Outlook 

The total Bipolar Depression market size and market size by therapies in Japan is also mentioned. 

Bipolar Depression Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Bipolar Depression market or expected to get launched in the market during the study period 2017-2030. The analysis covers Bipolar Depression market uptake by drugs; patient uptake by therapies; and sales of each drug.    


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Bipolar Depression Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Bipolar Depression key players involved in developing targeted therapeutics. 


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Bipolar Depression emerging therapies.

Reimbursement Scenario in Bipolar Depression

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 

KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Bipolar Depression domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Bipolar Depression market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 

Competitive Intelligence Analysis 

We perform Competitive and Market Intelligence analysis of the Bipolar Depression Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The Bipolar Depression report covers the descriptive overview of Bipolar Depression, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Bipolar Depression epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Bipolar Depression are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Bipolar Depression market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The Bipolar Depression report provides an edge while developing business strategies, by understanding trends shaping and driving the global Bipolar Depression market

Report Highlights

  • In the coming years, Bipolar Depression market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Bipolar Depression R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Bipolar Depression. Launch of emerging therapies will significantly impact the Bipolar Depression market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bipolar Depression
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Bipolar Depression Report Insights

  • Bipolar Depression Patient Population
  • Bipolar Depression Therapeutic Approaches
  • Bipolar Depression Pipeline Analysis
  • Bipolar Depression Market Size and Market Trends
  • Bipolar Depression Market Opportunities
  • Impact of upcoming Bipolar Depression Therapies

Bipolar Depression Report Key Strengths

  • 11 Years Bipolar Depression Forecast
  • Bipolar Depression 7MM Coverage 
  • Bipolar Depression Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Bipolar Depression Market
  • Bipolar Depression Drugs Uptake

Bipolar Depression Report Assessment

  • Current Treatment Practices
  • Bipolar Depression Unmet Needs
  • Bipolar Depression Pipeline Product Profiles
  • Bipolar Depression Market Attractiveness
  • Bipolar Depression Market Drivers and Bipolar Depression Market Barriers

Key Questions

Market Insights:

  • What was the Bipolar Depression market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Bipolar Depression total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Bipolar Depression market size during the forecast period (2017-2030)?
  • At what CAGR, the Bipolar Depression market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Bipolar Depression market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Bipolar Depression market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Bipolar Depression?
  • What is the historical Bipolar Depression patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Bipolar Depression in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Bipolar Depression?
  • Out of all 7MM countries, which country would have the highest prevalent population of Bipolar Depression during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Bipolar Depression treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Bipolar Depression in the USA, Europe, and Japan?
  • What are the Bipolar Depression marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Bipolar Depression?
  • How many therapies are developed by each company for Bipolar Depression treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Bipolar Depression treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Bipolar Depression therapies? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Bipolar Depression and their status?
  • What are the key designations that have been granted for the emerging therapies for Bipolar Depression?
  • What are the global historical and forecasted market of Bipolar Depression?

Reasons to buy

  • The Bipolar Depression report will help in developing business strategies by understanding trends shaping and driving the Bipolar Depression market
  • To understand the future market competition in the Bipolar Depression market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Bipolar Depression in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Bipolar Depression market
  • To understand the future market competition in the Bipolar Depression market

1. Key Insights

2. Executive Summary of Bipolar Depression

3. Bipolar Depression Market Overview at a Glance

3.1.   Market Share (%) Distribution of Bipolar Depression in 2017

3.2.   Market Share (%) Distribution of Bipolar Depression in 2030

4. Disease Background and Overview: Bipolar Depression

4.1.   Introduction

4.2.   Classification of Bipolar Disorder According to DSM-5

4.3.   Symptoms

4.4.   Causes

4.5.   Risk Factors

4.6.   Pathophysiology

4.7.   Genetics Findings in Bipolar Disorder

4.8.   Biomarkers

4.9.   Diagnosis

4.9.1. Diagnostic Guidelines

5. Case Reports

5.1.   Bipolar II Disorder: Case Study

5.2.   Clinical Characteristics and Legal Consequences of Violent Behavior: A Case of Bipolar Disorder

5.3.   Effectiveness of Simple Individual Psychoeducation for Bipolar II Disorder

6. Epidemiology and Patient Population

6.1.   Key Findings

6.2.   KOL Views

6.3.   Epidemiology Methodology

6.4.   Total Diagnosed Prevalent Cases of Bipolar Depression in the 7MM

7. United States Epidemiology

7.1.   Assumptions and Rationale

7.2.   Total Diagnosed Prevalent Cases of Bipolar Depression in the United States

7.3.   Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the United States

7.4.   Severity-specific Diagnosed Prevalent cases of Bipolar Depression in the United States

8. EU5 Epidemiology

8.1.   Germany Epidemiology

8.1.1. Assumptions and Rationale

8.1.2. Total Diagnosed Prevalent Cases of Bipolar Depression in Germany

8.1.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany

8.1.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany

8.2.   France Epidemiology

8.2.1. Assumptions and Rationale

8.2.2. Total Diagnosed Prevalent Cases of Bipolar Depression in France

8.2.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in France

8.2.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in France

8.3.   Italy Epidemiology

8.3.1. Assumptions and Rationale

8.3.2. Total Diagnosed Prevalent Cases of Bipolar Depression in Italy

8.3.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy

8.3.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy

8.4.   Spain Epidemiology

8.4.1. Assumptions and Rationale

8.4.2. Total Diagnosed Prevalent Cases of Bipolar Depression in Spain

8.4.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain

8.4.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain

8.5.   United Kingdom Epidemiology

8.5.1. Assumptions and Rationale

8.5.2. Total Diagnosed Prevalent Cases of Bipolar Depression in the UK

8.5.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK

8.5.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK

9. Japan Epidemiology

9.1.   Assumptions and Rationale

9.2.   Total Diagnosed Prevalent Cases of Bipolar Depression in Japan

9.3.   Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan

9.4.   Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan

10.  Current Treatment and Medical Practices

10.1.   Treatment of Bipolar Disorder

10.1.1.   Treatment Algorithm

10.1.2.   Treatment Guideline

11.  Unmet needs

12.  Marketed Drugs

12.1.  Vraylar (Cariprazine): Allergan (AbbVie)/Gedeon Richter

12.1.1.   Product Description

12.1.2.   Regulatory Milestones

12.1.3.   Other Development Activities

12.1.4.   Clinical Development

12.1.5.   Safety and Efficacy

12.1.6.   Product Profile

12.2.   Latuda (Lurasidone Hydrochloride): Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)

12.2.1.   Product Description

12.2.2.   Regulatory Milestones

12.2.3.   Other Development Activities

12.2.4.   Clinical Development

12.2.5.   Safety and Efficacy

12.2.6.   Product Profile

13.  Emerging Drugs

13.1. Key Cross Competition

13.2.  Abilify (Aripiprazole): Otsuka Pharmaceutical

13.2.1.   Product Description

13.2.2.   Other Developmental Activities

13.2.3.   Clinical Development

13.2.4.   Safety and Efficacy

13.2.5.   Product Profile

13.3.  Lumateperone/ITI-007: Intra-cellular Therapies

13.3.1.   Product Description

13.3.2.   Other Developmental Activities

13.3.3.   Clinical Development

13.3.4.   Product Profile

13.4.   NRX-100/NRX-101: NeuroRx

13.4.1.   Product Description

13.4.2.   Other Developmental Activities

13.4.3.   Clinical Development

13.4.4.   Product Profile

13.5.   Psilocybin: COMPASS Pathways

13.5.1.   Product Description

13.5.2.   Other Developmental Activities

13.5.3.   Clinical Development

13.5.4.   Product Profile

13.6.    Zuranolone (SAGE-217): Sage Therapeutics

13.6.1.   Product Description

13.6.2.   Other Developmental Activities

13.6.3.   Clinical Development

13.6.4.   Product Profile

13.7.    SEP-4199: Sunovion/Sumitomo Dainippon Pharma

13.7.1.   Product Description

13.7.2.   Other Developmental Activities

13.7.3.   Clinical Development

13.7.4.   Product Profile

13.8.    ILT101: Iltoo Pharma

13.8.1.   Product Description

13.8.2.   Clinical Development

13.8.3.   Product Profile

13.9.    Falkieri (Esketamine DPI): Celon Pharma

13.9.1.   Product Description

13.9.2.   Other Developmental Activities

13.9.3.   Clinical Development

13.9.4.   Product Profile

14.  Bipolar Depression: 7MM Market Analysis

14.1. Key Findings

14.2. Market Methodology

14.3. Attribute Analysis

14.4. Key Market Forecast Assumptions

14.5. Market Size of Bipolar Depression in the 7MM

14.6. Market Size of Bipolar Depression by Therapies in the 7MM

15.  United States Market Outlook

15.1. United States Market Size

15.1.1. Total market size of Bipolar Depression in the United States

15.1.2. Market Size of Bipolar Depression by Therapies in the US

16.  EU-5 Market Outlook

16.1. Germany Market Size

16.1.1. Total Market size of Bipolar Depression in Germany

16.1.2. Market Size of Bipolar Depression by therapies in Germany

16.2. France Market Size

16.2.1. Total Market size of Bipolar Depression in France

16.2.2. Market Size of Bipolar Depression by therapies in France

16.3. Italy Market Size

16.3.1. Total Market size of Bipolar Depression in Italy

16.3.2. Market Size of Bipolar Depression by therapies in Italy

16.4. Spain Market Size

16.4.1. Total Market size of Bipolar Depression in Spain

16.4.2. Market Size of Bipolar Depression by therapies in Spain

16.5. United Kingdom Market Size

16.5.1. Total Market size of Bipolar Depression in the United Kingdom

16.5.2. Market Size of Bipolar Depression by therapies in the UK

17.  Japan Market Outlook

17.1. Japan Market Size

17.1.1. Total Market size of Bipolar Depression in Japan

17.1.2. Market Size of Bipolar Depression by therapies in Japan

18.  Market Drivers

19.  Market Barriers

20.  SWOT Analysis

21.  Reimbursement and Market Access

22.  Appendix

22.1. Bibliography

22.2. Report Methodology

23.  DelveInsight Capabilities

24.  Disclaimer

25.  About DelveInsight

List of Tables

Table 1 Summary of Bipolar Depression, Market, Epidemiology and Key Events (2017–2030)

Table 2 Symptoms associated with manic and depressive episodes

Table 3 GWAS findings in bipolar disorder

Table 4 Main findings of circulating biomarkers in bipolar disorder

Table 5 Total Diagnosed Prevalent Cases of Bipolar Depression in the 7MM (2017–2030)

Table 6 Total Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)

Table 7 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)

Table 8 Severity-specific Diagnosed Prevalent cases of Bipolar Depression in the US (2017–2030)

Table 9 Total Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)

Table 10 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)

Table 11 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)

Table 12 Total Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)

Table 13 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)

Table 14 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)

Table 15 Total Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)

Table 16 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)

Table 17 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)

Table 18 Total Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)

Table 19 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)

Table 20 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)

Table 21 Total Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)

Table 22 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)

Table 23 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)

Table 24 Total Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)

Table 25 Total Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)

Table 26 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)

Table 27 Agents approved by the US FDA for acute bipolar mania, bipolar depression, and maintenance

Table 28 Categories of evidence (CE) and grade of recommendation (RG) for pharmacological and physical treatments used in acute Bipolar I depression (in alphabetical order within one category of evidence)

Table 29 Overall Recommendation Grades for long-term treatment

Table 30 Traditional evidence categories

Table 31 Vraylar (Cariprazine), Clinical Trial Description, 2020

Table 32 Vraylar (Cariprazine), Clinical Trial Description, 2020, Continued

Table 33 Latuda (Lurasidone Hydrochloride), Clinical Trial Description, 2020

Table 34 Latuda (Lurasidone Hydrochloride), Clinical Trial Description, 2020, Continued

Table 35 Key-Cross of Emerging Therapies

Table 36 Abilify (Aripiprazole), Clinical Trial Description, 2020

Table 37 Lumateperone (ITI-007), Patent Details

Table 38 Lumateperone (ITI-007), Clinical Trial Description, 2020

Table 39 NRX-100/NRX-101, Clinical Trial Description, 2020

Table 40 Psilocybin, Clinical Trial Description, 2020

Table 41 SAGE-217, Clinical Trial Description, 2020

Table 42 SEP-4199, Clinical Trial Description, 2020

Table 43 ILT101, Clinical Trial Description, 2020

Table 44 Falkieri (Esketamine), Clinical Trial Description, 2020

Table 45 Market Assumptions for Vraylar/Reagila

Table 46 Market Assumptions for Abilify

Table 47 Market Assumptions for Lumateperone/ITI-007

Table 48 Market Assumptions for NRX-100/NRX-101

Table 49 Market Assumptions for Zuranolone

Table 50 Market Assumptions for SEP-4199

Table 51 Market Assumptions for Falkieri

Table 52 Market Size of Bipolar Depression in the 7MM in USD Million (2017–2030)

Table 53 Market Size of Bipolar Depression by therapies in the 7MM, in USD Million (2017–2030)

Table 54 The US Market Size of Bipolar Depression in USD Million (2017–2030)

Table 55 Market Size of Bipolar Depression by therapies in the US, in USD Million (2017–2030)

Table 56 Germany Market Size of Bipolar Depression in USD Million (2017–2030)

Table 57 Market Size of Bipolar Depression by therapies in Germany, in USD Million (2017–2030)

Table 58 France Market Size of Bipolar Depression in USD Million (2017–2030)

Table 59 Market Size of Bipolar Depression by therapies in France, in USD Million (2017–2030)

Table 60 Italy Market Size of Bipolar Depression in USD Million (2017–2030)

Table 61 Market Size of Bipolar Depression by therapies in Italy, in USD Million (2017–2030)

Table 62 Spain Market Size of Bipolar Depression in USD Million (2017–2030)

Table 63 Market Size of Bipolar Depression by therapies in Spain, in USD Million (2017–2030)

Table 64 The UK Market Size of Bipolar Depression in USD Million (2017–2030)

Table 65 Market Size of Bipolar Depression by therapies in the UK, in USD Million (2017–2030)

Table 66 Japan Market Size of Bipolar Depression in USD Million (2017–2030)

Table 67 Market Size of Bipolar Depression by therapies in Japan, in USD Million (2017–2030)

List of Figures

Figure 1 Main subtypes of bipolar disorder

Figure 2 Symptoms of bipolar disorder

Figure 3 Effects of bipolar disorder on the body

Figure 4 Causes of bipolar disorder

Figure 5 Triggers in bipolar disorder

Figure 6 Multifactorial model of bipolar disorders

Figure 7 Symptoms with potential diagnostic utility in bipolar and unipolar depression

Figure 8 United States KOL Views

Figure 9 EU-5 and Japan KOL Views

Figure 10 Total Diagnosed Prevalent Cases of Bipolar Depression in the 7MM (2017–2030)

Figure 11 Total Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)

Figure 12 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)

Figure 13 Severity-specific Diagnosed Prevalent cases of Bipolar Depression in the US (2017–2030)

Figure 14 Total Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)

Figure 15 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)

Figure 16 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)

Figure 17 Total Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)

Figure 18 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)

Figure 19 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)

Figure 20 Total Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)

Figure 21 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)

Figure 22 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)

Figure 23 Total Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)

Figure 24 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)

Figure 25 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)

Figure 26 Total Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)

Figure 27 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)

Figure 28 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)

Figure 29 Total Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)

Figure 30 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)

Figure 31 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)

Figure 32 Algorithm for the Treatment of Mania/Hypomania

Figure 33 Algorithm for the Treatment of Depression in Bipolar Disorder*

Figure 34 Unmet needs

Figure 35 Market Size of Bipolar Depression in the 7MM in USD Million (2017–2030)

Figure 36 Market Size of Bipolar Depression by therapies in the 7MM, in USD Million (2017–2030)

Figure 37 Market Size of Bipolar Depression in the US, USD Millions (2017–2030)

Figure 38 Market Size of Bipolar Depression by therapies in the US, in USD Million (2017–2030)

Figure 39 Market Size of Bipolar Depression in Germany, USD Millions (2017–2030)

Figure 40 Market Size of Bipolar Depression by therapies in Germany, in USD Million (2017–2030)

Figure 41 Market Size of Bipolar Depression in France, USD Millions (2017–2030)

Figure 42 Market Size of Bipolar Depression by therapies in France, in USD Million (2017–2030)

Figure 43 Market Size of Bipolar Depression in Italy, USD Millions (2017–2030)

Figure 44 Market Size of Bipolar Depression by therapies in Italy in USD Million (2017–2030)

Figure 45 Market Size of Bipolar Depression in Spain, USD Millions (2017–2030)

Figure 46 Market Size of Bipolar Depression by therapies in Spain in USD Million (2017–2030)

Figure 47 Market Size of Bipolar Depression in the UK, USD Millions (2017–2030)

Figure 48 Market Size of Bipolar Depression by therapies in the UK in USD Million (2017–2030)

Figure 49 Market Size of Bipolar Depression in Japan, USD Millions (2017–2030)

Figure 50 Market Size of Bipolar Depression by therapies in Japan in USD Million (2017–2030)

Figure 51 Market Drivers

Figure 52 Market Barriers

Figure 53 SWOT analysis

Allergan (AbbVie)/Gedeon Richter

Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)

Otsuka Pharmaceutical

Intra-cellular Therapies

NeuroRx

COMPASS Pathways

Sage Therapeutics

Sunovion/Sumitomo Dainippon Pharma

Iltoo Pharma

Celon Pharma

  • Tags:
  • Bipolar Depression market
  • Bipolar Depression market research
  • Bipolar Depression market insight
  • Bipolar Depression market trends
  • Bipolar Depression market forecast
  • Bipolar Depression market share
  • Bipolar Depression pipeline drugs
  • Bipolar Depression treatment algori...
  • Bipolar Depression drugs
  • Bipolar Depression sales forecastin...
  • Bipolar Depression market size
  • Bipolar Depression disease
  • Bipolar Depression epidemiology
  • Bipolar Depression

Forward to Friend

Need A Quote